In the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial [14], 4401 patients with T2D and CKD were randomized to receive SGLT-2 inhibitor therapy with canagliflozin at a dose of 100 mg/day or placebo. This evidence concerns the gene SLC5A2 and diabetes mellitus.